Chris Shibutani
Stock Analyst at Goldman Sachs
(2.87)
# 1,590
Out of 5,124 analysts
96
Total ratings
54%
Success rate
6.45%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $46.14 | +116.73% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $3.72 | -19.35% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $14.85 | +1.01% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $27.98 | +14.37% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $95.20 | +43.91% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $21.01 | +57.07% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $487.25 | -38.02% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $38.64 | +31.99% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $206.95 | -25.10% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $12.08 | -66.89% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $7.17 | +178.94% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,074.68 | -32.72% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $17.88 | +45.41% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $141.83 | +7.88% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $228.49 | -24.29% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $42.28 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $53.94 | +27.92% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.99 | -34.97% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $79.65 | -71.12% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $9.03 | +453.71% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $77.81 | -33.17% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $24.90 | +140.96% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $10.28 | +75.10% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $8.86 | +91.87% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.60 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.83 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.95 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $46.14
Upside: +116.73%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $3.72
Upside: -19.35%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $14.85
Upside: +1.01%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $27.98
Upside: +14.37%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $95.20
Upside: +43.91%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $21.01
Upside: +57.07%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $487.25
Upside: -38.02%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $38.64
Upside: +31.99%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $206.95
Upside: -25.10%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $12.08
Upside: -66.89%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $7.17
Upside: +178.94%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,074.68
Upside: -32.72%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $17.88
Upside: +45.41%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $141.83
Upside: +7.88%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $228.49
Upside: -24.29%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $42.28
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $53.94
Upside: +27.92%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.99
Upside: -34.97%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $79.65
Upside: -71.12%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $9.03
Upside: +453.71%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $77.81
Upside: -33.17%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $24.90
Upside: +140.96%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $10.28
Upside: +75.10%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $8.86
Upside: +91.87%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.60
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.83
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.95
Upside: -